<p>宾夕法尼亚州普利茅斯会议——（商业资讯）——Harmony Biosciences Holdings, Inc.（纳斯达克：HRMY）今天宣布，将于 2026 年 2 月 24 日美国金融市场开盘前发布 2025 年第四季度和全年财务业绩。Harmony 将在 2026 年 2 月 24 日上午 8:30（东部时间）召开电话会议和网络直播，以讨论业绩。</p>
<p>要参加此次电话会议，请拨打 800-274-7083（国内）或 203-518-9786（国际），并引用密码 HRMYQ425。建议您至少在会议开始前 10 分钟拨入。</p>
<p>此次电话会议的直播和重播网络直播将在我们网站的投资者页面上提供，网址为 https://ir.harmonybiosciences.com/。</p>
<p><strong>关于 Harmony Biosciences</strong></p>
<p>Harmony Biosciences 是一家致力于为有未满足医疗需求的罕见神经疾病患者开发和商业化创新疗法的制药公司。Harmony Biosciences 以新颖的科学、远见的思维和对被忽视者的承诺为动力，培育一个充满治疗可能性的未来，使罕见神经疾病患者能够真正茁壮成长。公司由 Paragon Biosciences, LLC 于 2017 年成立，总部位于宾夕法尼亚州普利茅斯会议。我们相信，当同情心与创新相遇时，更美好的未来就能开始；这一愿景在我们推进的治疗创新、我们培养的文化以及我们支持的社区项目中得以体现。欲了解更多信息，请访问 www.harmonybiosciences.com。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAyMTAyODc4NDdyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAyMTAyODc4NDdyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20260210287847/en/</p>
<p><strong>投资者联系：</strong> Matthew Beck</p>
<p>astr partners</p>
<p>917-415-1750</p>
<p>matthew.beck@astrpartners.com</p>
<p><strong>媒体联系：</strong></p>
<p>Cate McCanless</p>
<p>Harmony Biosciences</p>
<p>202-641-6086</p>
<p>cmccanless@harmonybiosciences.com</p>
<p>来源：Harmony Biosciences Holdings, Inc.</p>

HRMY

<p>Harmony Biosciences Holdings, Inc.（纳斯达克代码：HRMY）将于 2026 年 2 月 24 日美国市场开盘前公布 2025 年第四季度和全年财务业绩。随后将在东部时间上午 8:30 举行电话会议和网络直播，以讨论业绩。参与者可以拨打 800-274-7083（国内）或 203-518-9786（国际）加入会议，密码为 HRMYQ425。Harmony Biosciences 专注于开发罕见神经疾病的治疗方案</p>

<p>PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on February 24, 2026, at 8:30 a.m. ET to discuss the results.</p>
<div class="lb-trans"><p>宾夕法尼亚州普利茅斯会议——（商业资讯）——Harmony Biosciences Holdings, Inc.（纳斯达克：HRMY）今天宣布，将于 2026 年 2 月 24 日美国金融市场开盘前发布 2025 年第四季度和全年财务业绩。Harmony 将在 2026 年 2 月 24 日上午 8:30（东部时间）召开电话会议和网络直播，以讨论业绩。</p>
</div><p>To participate in the call, please dial 800-274-7083 (domestic) or 203-518-9786 (international), and reference passcode HRMYQ425. It is recommended that you dial in at least 10 minutes prior to the call.</p>
<div class="lb-trans"><p>要参加此次电话会议，请拨打 800-274-7083（国内）或 203-518-9786（国际），并引用密码 HRMYQ425。建议您至少在会议开始前 10 分钟拨入。</p>
</div><p>The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.</p>
<div class="lb-trans"><p>此次电话会议的直播和重播网络直播将在我们网站的投资者页面上提供，网址为 https://ir.harmonybiosciences.com/。</p>
</div><p><strong>About Harmony Biosciences</strong></p>
<div class="lb-trans"><p><strong>关于 Harmony Biosciences</strong></p>
</div><p>Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa, we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.</p>
<div class="lb-trans"><p>Harmony Biosciences 是一家致力于为有未满足医疗需求的罕见神经疾病患者开发和商业化创新疗法的制药公司。Harmony Biosciences 以新颖的科学、远见的思维和对被忽视者的承诺为动力，培育一个充满治疗可能性的未来，使罕见神经疾病患者能够真正茁壮成长。公司由 Paragon Biosciences, LLC 于 2017 年成立，总部位于宾夕法尼亚州普利茅斯会议。我们相信，当同情心与创新相遇时，更美好的未来就能开始；这一愿景在我们推进的治疗创新、我们培养的文化以及我们支持的社区项目中得以体现。欲了解更多信息，请访问 www.harmonybiosciences.com。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAyMTAyODc4NDdyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260210287847r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260210287847/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20260210287847/en/</p>
</div><p><strong>Investor Contact:</strong> Matthew Beck</p>
<div class="lb-trans"><p><strong>投资者联系：</strong> Matthew Beck</p>
</div><p>astr partners</p>
<div class="lb-trans"><p>astr partners</p>
</div><p>917-415-1750</p>
<div class="lb-trans"><p>917-415-1750</p>
</div><p>matthew.beck@astrpartners.com</p>
<div class="lb-trans"><p>matthew.beck@astrpartners.com</p>
</div><p><strong>Media Contact:</strong></p>
<div class="lb-trans"><p><strong>媒体联系：</strong></p>
</div><p>Cate McCanless</p>
<div class="lb-trans"><p>Cate McCanless</p>
</div><p>Harmony Biosciences</p>
<div class="lb-trans"><p>Harmony Biosciences</p>
</div><p>202-641-6086</p>
<div class="lb-trans"><p>202-641-6086</p>
</div><p>cmccanless@harmonybiosciences.com</p>
<div class="lb-trans"><p>cmccanless@harmonybiosciences.com</p>
</div><p>Source: Harmony Biosciences Holdings, Inc.</p>
<div class="lb-trans"><p>来源：Harmony Biosciences Holdings, Inc.</p>
</div>

Harmony Biosciences 将于2026年2月24日公布 2025 年第四季度及全年财务业绩 | HRMY 股票新闻